You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Optimized AAV Serotype Vectors for Human Gene Therapy

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Sample-free onsite detection of cocaine using microneedles via laser-treated skin

    SBC: AFASCI, INC.            Topic: NIDA

    DESCRIPTION provided by applicant The abuse of illicit drugs such as cocaine marijuana and heroin remains a critical public health concern throughout the country and is associated with staggering economic and social consequences Cocaine remains the most frequently recorded illicit drug in emergency hospital visits and the leading cause of drug related deaths in the United States Since as hi ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A universal vaccine for the prevention of meningococcal meningitis in Africa

    SBC: OMVAX INC            Topic: R

    For more than years sub Saharan Africa has suffered with high rates of endemic meningococcal disease and periodic epidemic epidemics involving over cases In a low cost serogroup A polysaccharide protein conjugate vaccine MenAfriVac was introduced in the region The vaccine confers protection against serogroup A MenA disease as well as asymptomatic nasopharyngeal MenA carria ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.

    SBC: Acumen Pharmaceuticals, Inc            Topic: NIA

    In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Protection and Treatment of the Ocular Surface Barrier

    SBC: PROTERIS BIOTECH, INC.            Topic: N

    DESCRIPTION provided by applicant Dry eye a group of disorders that affects million people over the age of in the USA today is characterized by inadequate hydration and lubrication of the ocular surface The final common pathway for all types of dry eye is disruption of the ocular surface barrier which can be assessed by quantifying uptake of water soluble dyes applied topically to the ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Single Cell Analysis via Nanoscale Tip Enhanced Laser Ablation Mass Spectrometry

    SBC: Anasys Instruments Corp.            Topic: NIGMS

    DESCRIPTION provided by applicant The goal of the proposed Phase II STTR research is to develop an imaging system capable of detecting and identifying biomolecules in cells and tissue sections with sub cellular spatial resolution The system combines an atomic force microscope AFM with mass spectrometry MS analysis and utilizes a unique tip enhanced laser ablation TELA method developed in ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Scalable, Cloud-Based Microbiome Big Data Analytics System

    SBC: WHOLE BIOME INC.            Topic: 400

    The human microbiome has emerged as a hitherto unknown causal factor in a number of disease ranging from cancer cardiovascular disease and obesity To understand the biochemical mechanisms of the human microbiome in these diseases researchers must be able to store biochemical pathway transcriptomic and metabolomic datasets in a coherent and compatible form We propose to construct a cloud ba ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Data Driven Intent Recognition Framework

    SBC: OTHER LAB, INC.            Topic: NSF13599

    A critical aspect of exoskeleton control that has to date introduced a performance limitation is the ability of the exoskeleton to recognize the intent of the operator so it can apply assistance to their desired motion. This intent recognition effort is typically solved using ad-hoc methods where subject matter experts make design decisions and tune transitions to identify intended maneuvers as re ...

    STTR Phase II 2016 Department of DefenseSpecial Operations Command
US Flag An Official Website of the United States Government